Search results for "Immunologic"

showing 10 items of 1115 documents

Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease

2013

Background Nasal polyposis frequently occurs within the clinical picture of aspirin-exacerbated respiratory disease (AERD). A derailed arachidonic acid metabolism is regarded to be part of the pathophysiology of AERD, and aspirin desensitization is the only causal therapeutic option, so far. The optimal maintenance dose of aspirin desensitization to prevent nasal polyp recurrence on the one hand and to minimize aspirin-related side-effects, on the other hand, is still a matter of debate. The aim of this trial was to investigate the efficacy and safety of a low-dose aspirin desensitization protocol. Methods After sinus surgery, 70 individuals with AERD were randomly allocated to a prospectiv…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologylaw.inventionDrug HypersensitivityQuality of lifeRandomized controlled trialRecurrencelawSurveys and QuestionnairesInternal medicineRespiratory HypersensitivitymedicineHumansImmunology and AllergyDesensitization (medicine)AspirinAspirinMaintenance dosebusiness.industryRespiratory diseaseMiddle Agedmedicine.diseasePathophysiologyClinical trialTreatment OutcomeDesensitization ImmunologicAnesthesiaQuality of LifeFemalebusinessFollow-Up Studiesmedicine.drugAllergy
researchProduct

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

2011

Abstract Immune thrombocytopenia (ITP) is an autoimmune disease with a complex pathogenesis. As in many B cell–related autoimmune diseases, rituximab (RTX) has been shown to increase platelet counts in some ITP patients. From an immunologic standpoint, the mode of action of RTX and the reasons underlying its limited efficacy have yet to be elucidated. Because splenectomy is a cornerstone treatment of ITP, the immune effect of RTX on this major secondary lymphoid organ was investigated in 18 spleens removed from ITP patients who were treated or not with RTX. Spleens from ITP individuals had follicular hyperplasia consistent with secondary follicles. RTX therapy resulted in complete B-cell de…

AdultMalemedicine.medical_treatmentImmunologySplenectomySpleenT-Lymphocytes RegulatoryBiochemistryAntibodies Monoclonal Murine-DerivedImmune systemimmune system diseaseshemic and lymphatic diseasesHumansImmunologic FactorsMedicineImmunobiologyAgedAutoimmune diseaseB-LymphocytesPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyMiddle AgedTh1 Cellsmedicine.diseaseLymphatic systemmedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenmedicine.drugBlood
researchProduct

Soluble Interleukin-2 Receptor Secretion Defectin Vitroin HLA-B8, DR3 Positive Subjects

1990

Several studies have shown that HLA-B8,DR3 positive subjects may display T cell dysfunctions. Recently, a soluble form of the receptor for IL-2 (sIL-2R) has been demonstrated in human sera and in vitro-stimulated culture supernatant from human T lymphocytes. In the present paper we report sIL-2R serum levels and sIL-2R production from peripheral blood mononuclear cells in HLA-B8,DR3 positive subjects. We found that HLA-B8,DR3 positive subjects have the highest values of serum sIL-2R, but comparing the values of these subjects with those of negative ones no significant difference was observed. As regards the in vitro production of sIL-2R, no difference exists for unstimulated cultures, where…

AdultMalemusculoskeletal diseasesInterleukin 2medicine.medical_specialtyAdolescentT cellImmunologyStimulationHuman leukocyte antigenBiologyLymphocyte Activationmedicine.disease_causePeripheral blood mononuclear cellAutoimmune DiseasesHLA-B8 AntigenAutoimmunityHLA-DR3 AntigenT-Lymphocyte Subsetsimmune system diseasesInternal medicinemedicineHumansImmunology and AllergyGenetic Predisposition to DiseaseReceptorSicilyCells CulturedImmunologic Deficiency SyndromesReceptors Interleukin-2Middle AgedIn vitroDiabetes Mellitus Type 1medicine.anatomical_structureEndocrinologySolubilityImmunologyLeukocytes MononuclearFemaleDisease SusceptibilityProtein Processing Post-Translationalmedicine.drugAutoimmunity
researchProduct

Double-blind, randomized, placebo-controlled trial of allergen-specific immunotherapy with the major allergen Alt a1

2019

Background: There have been few studies conducted on the efficacy and safety of specific immunotherapy with allergen extracts of fungi compared with other allergen extracts, and there are no data on the major allergen Alt a 1 of the fungus Alternaria alternata. Objectives: We sought to evaluate the efficacy and safety of subcutaneous immunotherapy with 2 different doses of Alt a 1 in patients with rhinoconjunctivitis caused by sensitization to A alternata. Method: We performed a multicenter, randomized, double-blind, placebo-controlled trial with Alt a 1 administered subcutaneously in patients with allergic rhinoconjunctivitis with or without controlled asthma aged 12 to 65 years. Three gro…

AdultMalesafetyAllergymedicine.medical_specialtyAllergen immunotherapyAl·lèrgiaAdolescentImmunologyefficacyPlacebo-controlled studyPlacebomedicine.disease_causeFungal ProteinsYoung AdultAllergenDouble-Blind Methodchildrensubcutaneous immunotherapyInternal medicinemedicineadultsImmunology and AllergyHumansmolecular immunotherapyAdverse effectChildAgedConjunctivitis AllergicAllergen immunotherapyIntention-to-treat analysisbusiness.industryrhinoconjunctivitisclinical trialAllergensImmunoglobulin EMiddle Agedmedicine.diseaseAsthmaClinical trialfungal allergyDesensitization ImmunologicImmunoglobulin GAlt a 1Femalebusinesspurified allergen
researchProduct

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared wit…

2011

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …

AdultMicrobiology (medical)medicine.medical_specialtyScheduleAdolescentImmunization SecondaryEnzyme-Linked Immunosorbent AssayAntibodies Virallaw.inventionYoung AdultAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansPapillomavirus VaccinesDosingHuman papillomavirusYoung adultbusiness.industryImmunogenicityhuman papillomavirus human papillomavirus vaccines adolescent immunology alternative dosing scheduleVaccinationvirus diseasesSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEuropeSafety profileInfectious DiseasesImmunizationPediatrics Perinatology and Child HealthImmunologyFemalebusiness
researchProduct

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosi…

2015

Background: Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth. Objective: To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients. Methods: We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was…

AdultPediatricsmedicine.medical_specialtyMultiple SclerosisBirth weightGerman03 medical and health sciences0302 clinical medicinePregnancyGermanymedicineBirth WeightHumansImmunologic Factors030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyPregnancy registryPregnancyInterferon betabusiness.industryMultiple sclerosisInfant NewbornAbnormalities Drug-InducedInterferon-betamedicine.diseaselanguage.human_languageBody HeightAbortion SpontaneousPregnancy ComplicationsFirst trimesterPregnancy Trimester FirstNeurologylanguagePremature BirthFemaleNeurology (clinical)business030217 neurology & neurosurgeryMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Gynecological adverse effects of natalizumab administration: Case report and review of the literature.

2018

Abstract Background Natalizumab is administered for the treatment of relapsing-remitting multiple sclerosis (RR-MS) with high disease activity.Natalizumab therapy has been associated with adverse effects, such as progressive multifocal leukoencephalopathy, liver damage, nasopharyngitis, urinary tract infection, urticaria, cephalgia, dizziness, fatigue, nausea, fever, rigidity, anxiety and gastroenteritis. Objective To describe a case of a woman with RR-MS who developed recurrent vaginitis on natalizumab administration. Methods Case report and review of the literature. Results The case of a 26-year-old Caucasian woman with RR-MS, who presented with recurrent vaginitis since the initiation of…

AdultPediatricsmedicine.medical_specialtyNauseaUrinary systemDisease03 medical and health sciences0302 clinical medicineNatalizumabMultiple Sclerosis Relapsing-RemittingmedicineHumansImmunologic Factors030212 general & internal medicineAdverse effectVaginitisbusiness.industryProgressive multifocal leukoencephalopathyMultiple sclerosisNatalizumabGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingNeurologyFemaleNeurology (clinical)medicine.symptombusinessGenital Diseases Female030217 neurology & neurosurgerymedicine.drugFollow-Up StudiesMultiple sclerosis and related disorders
researchProduct

The Maternal Cytokine and Chemokine Profile of Naturally Conceived Gestations Is Mainly Preserved duringIn VitroFertilization and Egg Donation Pregna…

2015

This prospective longitudinal study aimed at comparing maternal immune response among naturally conceived (NC;n=25),in vitrofertilization (IVF;n=25), and egg donation (ED;n=25) pregnancies. The main outcome measures were, firstly, to follow up plasma levels of interleukin (IL) 1beta, IL2, IL4, IL5, IL6, IL8, IL10, IL17, interferon gamma, tumor necrosis factor-alpha (TNFα), transforming growth factor-beta (TGFβ), regulated upon activation normal T-cell expressed and secreted (RANTES), stromal cell-derived factor 1 alpha (SDF1α), and decidual granulocyte-macrophage colony-stimulating factor (GM-CSF) during the three trimesters of pregnancy during the three trimesters of pregnancy; secondly, t…

AdultProteomicslcsh:Immunologic diseases. Allergymedicine.medical_specialtyChemokineArticle SubjectT-Lymphocytesmedicine.medical_treatmentImmunologyFertilization in VitroPreeclampsiaPregnancyInternal medicinemedicineCluster AnalysisHumansImmunology and AllergyLongitudinal StudiesProspective StudiesInterleukin 8Pregnancy TrimestersPregnancyIn vitro fertilisationbiologybusiness.industryImmunityPregnancy OutcomeGeneral Medicinemedicine.diseaseInterleukin 10Endocrinologybiology.proteinCytokinesGestationFemalePregnancy TrimestersChemokineslcsh:RC581-607businessBiomarkersResearch ArticleJournal of Immunology Research
researchProduct

Immunologic diseases and brain tumors

2010

To do a bibliographic review of the given association of atopic [AD] and immunological diseases with central nerve system tumors [CNST] described a few years ago and to know the knowledge available. It gives an overview of the studies describing this association, and those explaining its mechanism. A negative association of AD with CNST stands out in case-control studies, which is not observed in cohort studies. The greatest association is seen for gliomas and is less significant for meningiomas. A clearer definition for the AD under study, tumour types, and the exact biochemical and clinical parameters to help diagnoses are the recommended as well as to establish an aetiologic and temporal…

AdultRiskPathologymedicine.medical_specialtyImmunologyMEDLINENegative associationBioinformaticsCohort StudiesImmunologic diseasesImmunology and AllergyMedicineAnimalsHumansChildPharmacologyClinical Trials as Topicbusiness.industryMechanism (biology)Brain NeoplasmsCase-control studyImmunityGeneral MedicineUnited StatesEuropeImmune System DiseasesCase-Control StudiesImmunological diseasesCentral nerve systembusinessCohort study
researchProduct

Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo

1996

The present study was designed to investigate in vivo immunomodulatory properties of hematopoietic growth factors. The influence on the activation of cytokine synthesis and on the expression of surface antigens associated with cellular activation of G-CSF or GM-CSF was investigated in cancer patients receiving these factors. One single dose of growth factor was administered to patients with bladder cancer (G-CSF group) or small cell lung cancer (GM-CSF group) before chemotherapy. After cytoreductive chemotherapy patients received supportive therapy with G-CSF or GM-CSF. Peripheral blood mononuclear cells and plasma samples were obtained for flow cytometry, Northern blot analysis, and assess…

AdultSialoglycoproteinsmedicine.medical_treatmentBiologyPeripheral blood mononuclear cellAdjuvants ImmunologicGranulocyte Colony-Stimulating FactormedicineHumansRNA MessengerGrowth SubstancesInterleukin 6AgedInterleukin-6MonocyteGrowth factorInterleukin-8Granulocyte-Macrophage Colony-Stimulating FactorReceptors Interleukin-1Receptors Interleukin-2HematologyGeneral MedicineMiddle AgedHematopoietic Stem CellsRecombinant ProteinsGranulocyte colony-stimulating factorInterleukin 1 Receptor Antagonist ProteinHaematopoiesisGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureCytokineSolubilityAntigens SurfaceImmunologyCancer researchbiology.proteinmedicine.drugAnnals of Hematology
researchProduct